‘Huidkankerpatiënten should be extra alert when using a medicine Cotellic’
Huidkankerpatiënten which was the means of cobimetinib either Cotellic use, have a greater chance of serious bleeding in the brain and the gastrointestinal system. Also, they run risk of more rapid degradation of muscle cells.
That warning Bijwerkingencentrum Lareb, although severe bleeding have not been reported.
Cobimetinib is in a limited number of hospitals used in combination with the drug vemurafenib, for metastatic skin cancer, or not to operate on skin cancer.
Users are doing there wise to find out how they signals of serious bleeding or rapid breakdown of muscles can recognize. To unusual bleeding, headache, dizziness, weakness, blood in the stool or the saliva they can better direct the physician. That they should certainly also do with muscle pain, muscle spasms, muscle weakness and dark or red-colored urine.
Doctors are advised to be especially alert to the means and on the patients who have to use it. They should use it well with the target audience dwell.